Zachary J. Kastenberg

Zachary J. Kastenberg

Auto-generated profile, based on publicly available information

Zachary J. Kastenberg

Division of Pediatric Surgery, Department of Surgery University of Utah Salt Lake City Utah USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
ZKZachary J. Kastenberg
Zachary J. Kastenberg
MTMark A. Taylor
Mark A. Taylor
MDMegan M. Durham
Megan M. Durham
CCCasey M. Calkins
Casey M. Calkins
RRRebecca M. Rentea
Rebecca M. Rentea
MRMichael D. Rollins
Michael D. Rollins

8 October 2021 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
KRKatie W. Russell
Katie W. Russell
SAShannon N. Acker
Shannon N. Acker
RIRomeo C. Ignacio
Romeo C. Ignacio
KLKatrine M. Lofberg
Katrine M. Lofberg
EGErin M. Garvey
Erin M. Garvey
AJAaron R. Jensen
Aaron R. Jensen

2 June 2023 in Annals of Surgery
Verified
Journal Article
Open access
BNBindi Naik-Mathuria
Bindi Naik-Mathuria
AUAlan F Utria
Alan F Utria
PEPeter F. Ehrlich
Peter F. Ehrlich
JAJennifer H. Aldrink
Jennifer H. Aldrink
AMAndrew Murphy
Andrew Murphy
DRDavid H. Rothstein
David H. Rothstein
Objective: The purpose of this study was to describe management and outcomes from a contemporary cohort of children with Wilms tumor complicated by inferior vena caval thrombus. Background: The largest series of these patients was published almost 2 decades ago. Since then, neoadjuvant chemotherapy has been commonly used to manage these patients, and outcomes have not been reported. Methods: Retrospective review of 19 North American centers between 2009 and 2019. Patient and disease characteristics, management, and outcomes were investigated and analyzed. Results: Of 124 patients, 81% had favorable histology (FH), and 52% were stage IV. IVC thrombus level was infrahepatic in 53 (43%), intrahepatic in 32 (26%), suprahepatic in 14 (11%), and cardiac in 24 (19%). Neoadjuvant chemotherapy using a 3-drug regimen was administered in 82% and postresection radiation in 90%. Thrombus level regression was 45% overall, with suprahepatic level showing the best response (62%). Cardiopulmonary bypass (CPB) was potentially avoided in 67%. The perioperative complication rate was significantly lower after neoadjuvant chemotherapy [(25%) vs upfront surgery (55%); P=0.005]. CPB was not associated with higher complications [CPB (50%) vs no CPB (27%); P=0.08]. Two-year event-free survival was 93% and overall survival was 96%, higher in FH cases (FH 98% vs unfavorable histology/anaplastic 82%; P=0.73). Neither incomplete resection nor viable thrombus cells affected event-free survival or overall survival. Conclusions: Multimodal therapy resulted in excellent outcomes, even with advanced-stage disease and cardiac extension. Neoadjuvant chemotherapy decreased the need for CPB to facilitate resection. Complete thrombectomy may not always be necessary.

1 March 2020 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
ZKZachary J. Kastenberg
Zachary J. Kastenberg
NWNatalie Wall
Natalie Wall
NMNeha Malhotra
Neha Malhotra
SZSarah Zobell
Sarah Zobell
LMLija Mammen
Lija Mammen
MRMichael D. Rollins
Michael D. Rollins

1 February 2019 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
MKMicah G. Katz
Micah G. Katz
ZKZachary J. Kastenberg
Zachary J. Kastenberg
MTMark A. Taylor
Mark A. Taylor
CBCarol D. Bolinger
Carol D. Bolinger
ESEric R. Scaife
Eric R. Scaife
KRKatie W. Russell
Katie W. Russell

31 March 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ZKZachary J. Kastenberg
Zachary J. Kastenberg
SSScott S. Short
Scott S. Short
KRKimberly J. Riehle
Kimberly J. Riehle
AUAlan Utria
Alan Utria
TLTimothy B. Lautz
Timothy B. Lautz
Reto M. BaertschigerReto M. Baertschiger
Reto M. Baertschiger